[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100449625":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":96,"collaborators":7,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":7,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":107,"phases":7,"briefSummary":108,"conditions":109,"keywords":7,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Celcuity Inc","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Gedatolisib","Gedatolisib is a potent, reversible dual inhibitor that selectively targets phosphoinositide 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in biochemical and cellular assays.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Nadene Zack, MS","CONTACT","844-310-3900","nzack@celcuity.com",[20,38,53,67,81],{"facility":21,"status":22,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"University of Alabama at Birmingham","AVAILABLE","Birmingham","Alabama","35233","United States","US",{"type":29,"coordinates":30},"Point",[31,32],-86.80249,33.52066,{"lat":32,"lon":31},[35],{"name":36,"role":16,"phone":7,"phoneExt":7,"email":37},"Erica Stringer-Reasor, MD","esreasor@uabmc.edu",{"facility":39,"status":22,"city":40,"state":41,"zip":42,"country":26,"countryCode":27,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"University of Michigan","Ann Arbor","Michigan","48109",{"type":29,"coordinates":44},[45,46],-83.74088,42.27756,{"lat":46,"lon":45},[49],{"name":50,"role":16,"phone":51,"phoneExt":7,"email":52},"Anne F Schott, MD","734-936-6266","aschott@med.umich.edu",{"facility":54,"status":22,"city":55,"state":56,"zip":57,"country":26,"countryCode":27,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"type":29,"coordinates":59},[60,61],-82.99879,39.96118,{"lat":61,"lon":60},[64],{"name":65,"role":16,"phone":7,"phoneExt":7,"email":66},"Robert Weslowski, MD","robert.wesolowski@osumc.edu",{"facility":68,"status":22,"city":69,"state":70,"zip":71,"country":26,"countryCode":27,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"The University of Texas MD Anderson Cancer Center","Houston","Texas","77030",{"type":29,"coordinates":73},[74,75],-95.36327,29.76328,{"lat":75,"lon":74},[78],{"name":79,"role":16,"phone":7,"phoneExt":7,"email":80},"Rachel Layman, MD","rlayman@mdanderson.org",{"facility":82,"status":22,"city":83,"state":84,"zip":85,"country":26,"countryCode":27,"cosmosGeoPoint":86,"geoPoint":90,"contacts":91},"Seattle Cancer Care Alliance","Seattle","Washington","98109",{"type":29,"coordinates":87},[88,89],-122.33207,47.60621,{"lat":89,"lon":88},[92],{"name":93,"role":16,"phone":94,"phoneExt":7,"email":95},"Jennifer Specht, MD","206-606-6768","jspecht@uw.edu",{"type":97,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100449625","expanded-access-protocol-for-subjects-previously-treated-with-gedatolisib-in-b2151009-100449625",false,"NCT05134922","Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009","Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in a Celcuity-Sponsored Clinical Study (B2151009)","Inclusion Criteria:\n\n1. Currently enrolled in the B2151009 clinical study and benefiting from treatment with gedatolisib in combination with other therapies as determined by the Investigator\n2. Previously demonstrated compliance and are willing and able to comply with scheduled visits, treatment plans, and other study procedures\n3. No evidence of progressive disease, as determined by the Investigator\n4. Provide written informed consent prior to enrolling and receiving treatment\n\nExclusion Criteria:\n\n1. Permanently discontinued from treatment in Study B2151009, or discontinued from Study B2151009 for any reason\n2. Women who are pregnant, intend to become pregnant, or nursing","FEMALE","18 Years","EXPANDED_ACCESS","Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.",[110],"Breast Neoplasm Malignant Female","2025-03-19",{"date":113,"type":114},"2025-03-21","ACTUAL",{"name":5,"class":6},5]